A Study of Efgartigimod in Patients With IgG4-Related Disease
Status:
NOT_YET_RECRUITING
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if efgartigimod can treat IgG4-related disease in adults. The main questions it aims to answer are:
In patients with IgG4-related disease, does treatment with efgartigimod reduce the volume of the:
* lacrimal gland(s) and/or
* salivary gland(s) and/or
* pancreas
Participants will:
* Receive efgartigimod once weekly for up to 12 weeks
* Visit the clinic every one to six weeks for checkups and tests
* Be asked to complete questionnaires to see how they feel on efgartigimod